Compounded Semaglutide and Compounded Tirzepatide vs. Branded: What Differs

A state-licensed pharmacy or a licensed physician prepared the product for a specific named patient under section 503A of the FD&C Act. Or an outsourcing facility prepared it under section 503B. This is a legally exempt way of making a drug for an individual case. It is not the same process as manufacturing an FDA-approved drug, and compounded product does not go through FDA premarket review.

It can be, within narrow conditions. The underlying substance has to be eligible for compounding, and the pharmacy has to follow 503A or 503B rules. The product cannot be 'essentially a copy' of an approved drug beyond FDA's four-prescriptions-per-month tolerance. Unapproved salt forms such as semaglutide sodium or semaglutide acetate fall outside that, because FDA states it is not aware of any lawful basis for using them.

FDA treats a compounded product as essentially a copy of a commercially available drug when it has the same active ingredient and the same route of administration. The strength must also be the same, similar, or easily substitutable. The exception is when a prescriber documents a significant difference for that patient. FDA has stated it does not intend to act against a compounder who fills four or fewer prescriptions of such a product per calendar month.

They are different salt forms of semaglutide, not the active ingredient used in the FDA-approved products (Ozempic, Wegovy, Rybelsus). FDA states that these salt forms are different active pharmaceutical ingredients from the one in the approved drugs. It is not aware of any lawful basis for using them in compounding.

No. FDA determined the tirzepatide shortage resolved in December 2024 and the semaglutide injection shortage resolved on February 21, 2025. Compounding during a declared shortage has more legal room than compounding afterward. The resolved shortages narrowed what compounders can lawfully do with either drug.

No. There is no evidence it works better, because a compounded product has not gone through the safety-and-effectiveness review that generated that evidence for the approved drugs (Mounjaro, Zepbound). A compounded product that truly contains tirzepatide at an equivalent strength may act the same way in the body. But the pharmacy that made it is not required to prove that, and some compounded products have substituted an unapproved substance instead of tirzepatide.

Not as of this writing. FDA proposed on April 30, 2026 to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list. The public comment period closed June 29, 2026, and FDA had not published a final decision as of this writing. That proposal targets the bulk-substance basis outsourcing facilities (503B) rely on. By itself it would not ban a pharmacist from compounding a patient-specific prescription under 503A.

Mounjaro's FDA label warns of a higher hypoglycemia risk when tirzepatide is combined with an insulin secretagogue such as a sulfonylurea, or with insulin. It says tirzepatide delays gastric emptying, so oral drugs with a narrow therapeutic index need monitoring. Oral hormonal contraceptives need a non-oral or barrier back-up method for four weeks after starting or each dose increase. The label carries a boxed warning on thyroid C-cell tumors seen in rodents. It is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. That guidance applies to tirzepatide itself. It only protects a patient using a compounded product if that product contains tirzepatide at the labelled strength, which the label's testing does not confirm for any compounder.

Ozempic and Wegovy's FDA label says not to use semaglutide together with other semaglutide products or other GLP-1 receptor agonists. It flags an added hypoglycemia risk when combined with insulin or a sulfonylurea. It also notes semaglutide slows stomach emptying, which can affect how well oral drugs with a narrow therapeutic index are absorbed, so those may need closer monitoring. As with tirzepatide, this interaction data was generated on the approved active ingredient, not on any specific compounded product.

There is no verified timeline for a compounded product. Published weight-loss results come from clinical trials of the FDA-approved drugs, dosed on the titration schedule tested in those trials. A compounding pharmacy is not required to follow that schedule or to show its product performs the same way. A number like weeks-to-lose-a-set-amount describes the approved drug's trial data, not any compounded formulation.

There is no fixed timeline to lose a specific number of pounds. It depends on dose, individual response and how long treatment continues. Mounjaro's FDA label reports population averages from trials, not personal milestones. In one monotherapy trial, average weight change at week 40 was about -6.3 kg (roughly 14 lb) on the 5 mg dose. It was about -7.8 kg (roughly 17 lb) on the 15 mg dose, and about -1.0 kg for placebo. In a combination-therapy trial, the 15 mg dose averaged about -11.3 kg (roughly 25 lb) at week 52. These are group averages from specific trials, not a guarantee for any individual. The label does not define a lose-20-lb milestone directly.

This is not established as a fixed timeline. Wegovy's FDA label sets out a dose-escalation schedule. It runs 0.25 mg for weeks 1 to 4 and 0.5 mg for weeks 5 to 8. Then it runs 1 mg for weeks 9 to 12 and 1.7 mg for weeks 13 to 16. A maintenance dose starts from week 17. Individual weight change depends on the person, the maintenance dose reached and how long treatment continues. I could not verify a specific pounds-lost figure tied to a specific week in the label, so I am not stating one here. Ask a prescriber what the trial data means for your own starting weight and dose.

The FDA label does not present 2.5 mg as a treatment dose. It is the starting dose, used only to reduce gastrointestinal side effects before increasing the dose. Mounjaro's label directs increasing it in 2.5 mg increments after at least 4 weeks, up to a maximum of 15 mg weekly in adults. The label's weight-loss results were measured at the higher doses (5 mg to 15 mg) reached after that escalation. They were not measured at the 2.5 mg starting dose alone.

No. I found no evidence it is more effective than Ozempic or Wegovy. The published results come from trials of the approved drugs. A compounded product skips that review, and its maker does not have to show it performs the same. Some products have used semaglutide sodium or acetate, which FDA says are not the approved active ingredient.

In narrower circumstances than before. The semaglutide injection shortage ended on February 21, 2025, removing the main legal opening. A 503A pharmacy can still fill a patient-specific prescription for a product that is not essentially a copy of the approved drug. It can also fill one that is a copy, within FDA's stated tolerance of four or fewer such prescriptions a month. FDA has proposed excluding semaglutide from the 503B bulks list, with no final decision as of this writing.

Ozempic is made by an FDA-approved manufacturer, went through full new drug application review, and contains the approved form of semaglutide. Compounded semaglutide is prepared by a licensed pharmacy or outsourcing facility and is exempt from premarket review. It may not contain the same ingredient, because some products have used unapproved salt forms. See the side-by-side table on this page.